Survival and desferrioxamine in thalassaemia major.
Modell B., Letsky EA., Flynn DM., Peto R., Weatherall DJ.
A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.